Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. - Wikidata - awgldk - TriplyDB

Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

http://www.wikidata.org/entity/Q34669675

about

In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells Adoptive immunotherapy for cancer: building on success Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Adoptive cell transfer: a clinical path to effective cancer immunotherapy Cancer regression in patients after transfer of genetically engineered lymphocytes Genetic engineering with T cell receptors Adoptive cell therapy for sarcoma In vivo imaging of therapy-induced anti-cancer immune responses in humans.T-cell receptor gene therapy--ready to go viral?Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.Novel human interleukin-15 agonists Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.Transduction of SIV-specific TCR genes into rhesus macaque CD8+ T cells conveys the ability to suppress SIV replication.Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins.Immunotherapy for metastatic solid cancers Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.Probing the effector and suppressive functions of human T cell subsets using antigen-specific engineered T cell receptors Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.Mouse model for pre-clinical study of human cancer immunotherapy.Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?Improving TCR Gene Therapy for Treatment of Haematological Malignancies.

P2860

Q21559398-E83D64FD-540E-4B21-BA42-BADCA94197D9 Q24546258-A007C888-BC97-403E-816C-EB6F5B59CE11 Q24623215-AB5932D7-7D93-4CF9-AA13-121850154862 Q24644774-EA45477D-79BB-4CFB-8021-870BF053F990 Q24654976-1B9158A3-DDEA-45F5-987F-362C1E123291 Q26995677-ABF3578D-0118-4DD3-B2E9-21959B6F4516 Q27009541-A31EBA82-5E52-48D6-9B0C-3029A0288839 Q27693338-9D8BDB41-85B1-4674-92A5-2E4AC0C6A2FB Q28081611-7AF9282F-8033-455A-BC74-30F7FBCB2249 Q30974719-7BD9B184-F8E6-475C-AC42-2C222626F2CF Q33261122-69CD0B95-E24D-482D-887E-E2BB56619D86 Q33303162-3548BEFF-E99B-48E5-A7F4-BFDEC558FBCF Q33623266-2F1A9A79-C7F0-40F6-8C54-A612A19D1786 Q33688441-630356E7-1563-40CE-8D76-FC5DB85398D5 Q34008900-03A570F6-F6D0-4B7E-9649-A043BB2308A6 Q34082215-A432A0F6-ECCE-4353-A8A6-55974E91E37D Q34084756-40C172F5-F6FD-460E-BC09-1257ED795FF9 Q34109953-5058FFCB-7B21-47C9-9FB7-8B45C3DFFFB3 Q34171679-C4D2F452-82BD-4C85-927D-298E86B1B1AE Q34219970-8C33B61B-81D1-459F-BA2E-4B3446102FDB Q34245416-3883417F-4522-4DEB-8776-9EFE3DF17A94 Q34309388-82626CCE-4BD1-4B13-A52C-415EE3AAD8DB Q34310912-31249CEA-AE57-45EE-8FD6-E112060722CA Q34338927-3412AB04-7A35-4575-BBBC-DE7C06673BCE Q34519488-21935448-5AC2-43F4-9004-E211CB9698FC Q34598553-89ECD726-2D07-4A7C-9CAB-81B952936A30 Q34657661-A70CDAF6-CDF2-4BA9-B575-A5D1614A4C9D Q34657676-B3CD6F9F-58A5-42C3-8992-A1D44E098084 Q34700939-28B732A4-ED34-4571-9447-EC276806F3E3 Q34757266-D7F8F514-269B-4D4B-9F59-FE1B448D39C6 Q34795354-E3D4DC56-8915-4F8F-A498-CEB2373AA137 Q35001971-4AB7DB52-3CC4-4675-A6FE-5128D4EB0E3C Q35135031-6F26270C-74DC-42FB-A3A1-D5AE21463503 Q35145144-88410BD6-E5DB-499D-A7CA-93425744840B Q35162266-48B354A8-BF17-427E-BE40-66BE1592D378 Q35181705-66EE5A7C-D2C9-40E7-8438-216CD0F72F8E Q35382043-0974D09E-37A7-4F03-A0F7-992339E3C198 Q35566748-02BBC363-FA61-4E13-8548-27E1AA9BE591 Q35594089-BCCB7222-C2AB-4994-B7B5-768C91222EDA Q35738738-9C816116-0311-4ACF-B785-97B5314A69D6

P2860

Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

http://www.wikidata.org/entity/Q34669675

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@ast

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@en

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@nl

type

label

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@ast

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@en

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@nl

prefLabel

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@ast

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@en

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@nl

P1433

Q34669675-E2B26466-2C99-46FE-BBCF-2BCCB83FBD81

P1476

Q34669675-957FF4D0-5C2B-488B-85C6-B3ACA8F5D7C4

P2093

Q34669675-032CC688-CE58-44C9-9926-602AD3712FBF

Q34669675-25024965-D2BE-4E68-82C1-5AB3AEF7B201

Q34669675-26470D24-D1C9-4810-AA3F-93A9610652C5

Q34669675-60D8CB9F-D347-4E06-9365-120551851D42

Q34669675-721B802C-5481-4764-9F6C-16B58CB55C66

Q34669675-8CBBF0FA-2142-4553-AB1F-2E4885E148FC

Q34669675-A032BBB1-4967-4A71-B78C-688D29F00352

Q34669675-B4E20B0B-EE2B-4FA3-8DDE-FF09D96D3BE6

Q34669675-B907FC03-0DAE-40F0-ABB4-4ECB4A87C81C

Q34669675-C793898E-C1A0-47C7-81E6-4F61C92D4B8F

P2860

Q34669675-0D945D4F-99D0-483F-AD2C-FA79A7EBB5EF

Q34669675-12697B7F-C27A-47F3-8161-54F5D7A4AD55

Q34669675-19FA4A7E-5820-4ABA-BF33-B55AF71FAD70

Q34669675-22ABB2A8-3502-43E6-920E-B98900B880DA

Q34669675-2753F0AD-D3DF-4190-91B1-546351A6A44D

Q34669675-3F64C0D2-2B53-4637-874E-1F4CABAD609A

Q34669675-54C00C72-8676-4692-83D4-30209C76BB6A

Q34669675-54C8C0DC-1724-41C7-B291-5A59EDD926C5

Q34669675-59C4FD4F-5C9F-4281-A24D-D2F61AA8AF1F

Q34669675-5E160C08-BF3E-4168-A58F-23393F7D5B72

P304

Q34669675-E994E9F7-CE62-40F8-9F22-BF825CEC054A

P31

Q34669675-278BE303-0ADF-4025-9F98-ED964E8EFBA3

P356

Q34669675-1C75A4B4-52F4-4C7E-A598-AC23EF678800

P433

Q34669675-484B5DFD-B9ED-412D-A41D-49B3111AFC3E

P478

Q34669675-F210B349-2271-4ED8-BF55-31B00DE0BF4A

P577

Q34669675-47698526-43A0-47F7-AD06-5FA4D5FBACB0

P5875

Q34669675-880F9D4C-9772-45C1-B7D4-9F76128AD6AB

P698

Q34669675-D4DBF1E9-584E-477F-86D9-8EB9B0BC41C0

P921

Q34669675-B75FE339-B78F-4960-B3DA-313C777C87E0

P932

Q34669675-E64ECE00-DDAA-43B8-8EFB-A31E5E132C04

P356

HUM.2005.16.457

P1433

Human Gene Therapy

P1476

Transfer of a TCR gene derived ...... ive T-cell effector functions.

@en

P2093

John Wunderlich

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Marybeth S Hughes

http://www.w3.org/2001/XMLSchema#string

Morvarid Moayeri

http://www.w3.org/2001/XMLSchema#string

Paul F Robbins

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Robert G Hawley

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Yik Y L Yu

http://www.w3.org/2001/XMLSchema#string

Yong Li

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.

Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.

Genetic engineering of T cell specificity for immunotherapy of cancer.

Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.

T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

Development of improved adenosine deaminase retroviral vectors.

P304

457-472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2005.16.457

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7866217

http://www.w3.org/2001/XMLSchema#string

P698

15871677

http://www.w3.org/2001/XMLSchema#string

P921

P932

1476695

http://www.w3.org/2001/XMLSchema#string